Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease

12Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of a 52-year-old woman with a 1-year history of rheumatoid arthritis-associated interstitial lung disease referred to hospital because of aggravated pulmonary symptoms in spite of intensive treatment including prednisone, azathioprine and triptergium glycoside. We subsequently initiated treatment with 25 mg of etanercept, subcutaneously injected twice weekly. Following 6 months of therapy with this agent, sustained improvement in dyspnea, cough was reported by the patient and respiratory function test showed marked improvement. The improvement was confrmed by reduced middle and lower lung markings on chest radiography and high-resolution CT scan. This report suggests etanercept may be effective in the treatment of rheumatoid arthritis-associated interstitial lung disease. © the author(s), publisher and licensee Libertas Academica Ltd.

Cite

CITATION STYLE

APA

Wang, Y., Xu, S. qian, Xu, J. hua, & Ding, C. (2011). Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clinical Medicine Insights: Case Reports, 4, 49–52. https://doi.org/10.4137/CCRep.S8150

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free